As capital flows into biotech face growing scrutiny around long-term value creation, sustainability is emerging as a defining lens for investment, strategy, and scale. This panel brings together a growth equity investor and a seasoned biotech executive to explore how responsible innovation is increasingly shaping investment decisions across the biotech ecosystem.
Drawing on deep experience across global healthcare investing, drug development, regulatory strategy, and AI-enabled innovation, the panel will explore how sustainability is moving from aspiration to execution—informing capital allocation, R&D priorities, partnership structures, and M&A decisions. Speakers will discuss what investors and boards are increasingly looking for in high-growth biotech companies, how scientific rigor and speed can coexist with sustainable practices, and where emerging platforms are creating durable, scalable advantage.
This conversation offers a candid look at how sustainable innovation is becoming a differentiator for capital formation and long-term growth across the biotech ecosystem—and what founders, investors, and executives need to understand to stay ahead.
